Next, we examined whether IFNα2a in combination with known SARS-CoV-2 inhibitors remdesivir, EIDD-2801, camostat, cycloheximide, or convalescent serum [35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52] can protect cells from virus infection more efficiently and at lower concentrations than IFNα2a alone. The gene discussed is IFNA2; the disease is viral infectious disease.